Silicon Valley Capital Partners’s Regenxbio RGNX Stock Holding History

Silicon Valley Capital Partners’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$144	Hold	12	–	–	﹤0.01%	414
2026 Q1	$101	Buy	+12	New	+$126	﹤0.01%	423

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Silicon Valley Capital Partners's RGNX Position: Q2 2026 in Review

Silicon Valley Capital Partners held its Regenxbio (RGNX) position steady in Q2 2026 at 12 shares worth $144. The position accounts for ﹤0.01% of the portfolio, ranked #414.

Silicon Valley Capital Partners first reported a position in RGNX in Q1 2026 and has held it in 2 quarters since. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

Silicon Valley Capital Partners held 12 shares of Regenxbio worth $144 as of Q2 2026.
Silicon Valley Capital Partners left its Regenxbio share count unchanged in Q2 2026.
Regenxbio made up ﹤0.01% of Silicon Valley Capital Partners's portfolio in Q2 2026, its #414 holding.
Silicon Valley Capital Partners first reported a position in Regenxbio in Q1 2026 and has held it in 2 quarters since.
165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Silicon Valley Capital Partners's 13F filing for Q2 2026, filed 21 Sep 2026.